KPET Ultra Paceline

This is the foundational filing for the SPAC. It establishes the trust value per share ($10.079676130434382 based on $200,000,000 / 19,841,880 public shares, though stated as $10.079676130434782), the 24/27-month deadline (April 1, 2028 / April 1, 2029), the redemption mechanics, and the insider lock-ups (Founder Shares: 180 days post-business combination or post-liquidation; Private Units: 30 days post-business combination). The sponsor forfeiture mechanism for the over-allotment is set (up to 750,000 Founder Shares). The independent directors bought in with founder shares, aligning their interests. The filing contains no information on a target, revenue, customers, or market size beyond the SPAC's blank-check nature.

Strategic Positioning & Pedigree Claims: Management attributes its acquisition framework to over 50 combined years of operational and investment experience, targeting underperforming assets in travel, industrials, technology, telecommunications, media, business services, and consumer products.

Accelerating the S-1 effectiveness date compresses the pre-offering timeline, which directly dictates when public shares begin trading, when shareholder redemption rights attach, and when the combined entity’s operational clock starts counting toward the 2028-03-30 deadline. The letter contains zero claims regarding customer concentration, historical or projected revenue, market sizing, technological roadmap, partnership arrangements, pending litigation, or sponsor conduct beyond the signatory CFO attribution.

This filing establishes the key terms for investors evaluating the SPAC IPO. Trust account per-share value is initially $10.00, but the actual trust value will include interest; the trust will hold $200 million ($230 million if over-allotment). The deadline to complete a business combination is 24 months from the closing of this offering, with one three-month extension at the sponsor's option. No business combination target has been identified. The sponsor (KPET Ultra Paceline LLC) and insiders have significant economic incentives and conflicts, as detailed in the prospectus. The restated financials highlight a material weakness in internal controls over financial reporting and a going concern uncertainty before the offering. Investors should note the sponsor's ability to forfeit or transfer founder shares and the redemption rights for public shareholders.

This filing establishes the full capital structure and redemption mechanics for the SPAC. It details the trust, the 24/27-month deadline, shareholder redemption rights (subject to a 15% cap on a single holder if a shareholder vote is used), the sponsor's nominal cost for founder shares ($0.004 each), and the anti-dilution protections that ensure founders retain 20%. It also discloses the sponsor's compensation ($20K/month administrative fee, reimbursement of up to $300K in organizational loans, and up to $1.5M in convertible working capital loans). The trust holds $10.00 per unit at IPO; the net tangible book value (NTBV) per share is detailed under various redemption scenarios, showing investors face immediate dilution of roughly 118% if all public shares are redeemed. Management claims extensive deal experience via prior SPACs (Pace-I/Playa, Pace Energy/Magnolia, Pace-II/Accel, Pace Tech/Nerdy, TPG Pace/Vacasa) but also notes two liquidations (Pace Beneficial Finance and Pace Beneficial II).

As outlined by the Registrant’s management and legal counsel, this filing constructs the entire pre-deal operating and equity framework, confirming that public capital will remain locked in trust while the Sponsor captures substantial asymmetric upside through founder shares issued at $0.004 and protected anti-dilution provisions guaranteeing a permanent 20% ownership block.

What changed: Joint filing agreement (Exhibit 99.1) attached to a Schedule 13G beneficial ownership report. This document discloses no changes to beneficial ownership percentages, voting power, or investment intent regarding KPET shares. It exclusively establishes a joint filing arrangement among five RP-affiliated vehicles—RP Investment Advisors LP, RP Select Opportunities Master Fund Ltd., RP Debt Opportunities Fund Ltd., RP Alternative Global Bond Fund, and RP Alternative Credit Opportunities Fund. The text contains no references to redemption deadlines, trust account mechanics, extension provisions, target identification progress, or sponsor conduct. Why it matters: While the filing provides no data on KPET’s search timeline, cash preservation, or shareholder action windows, it administratively consolidates regulatory reporting obligations for the listed funds. Each vehicle will rely on the same joint filing framework to meet Section 13 disclosure requirements, as executed by Richard Pilosof in his capacity as Chief Executive Officer of the general partner. For investors tracking capital commitment signals or activist positioning, this structure clarifies that the RP entities are bundling their disclosures rather than signaling independent strategic shifts, changes in sponsorship authority, or updates to the company’s operational cadence.

What changed: A Form 8-K current report accompanied by a pro forma unaudited balance sheet, functioning as a routine post-offering compliance filing that discloses the completion of the initial public offering, the simultaneous private placement, and the full exercise of the underwriter’s over-allotment option. According to the filing, on April 1, 2026, KPET Ultra Paceline Corporation completed its IPO of 20,000,000 units generating $200,000,000 in gross proceeds, and simultaneously closed a private placement of 235,000 units to KPET Ultra Paceline Unit Holdings, LLC for $2,350,000. The document states that on April 15, 2026, the underwriter fully exercised its over-allotment option, purchasing 3,000,000 additional units for $30,000,000, which were consummated on April 20, 2026. Per the registrant's disclosure, a total of $230,000,000, inclusive of $12,650,000 of deferred underwriting discounts and commissions, was deposited into a trust account administered by Continental Stock Transfer & Trust Company. The pro forma balance sheet records 23,000,000 Class A ordinary shares subject to possible redemption at a stated redemption value of $10.00 per share. The filing further notes that the complete exercise of the over-allotment permanently removed forfeiture conditions on 750,000 Class B ordinary founder shares, establishing a final outstanding founder share count of 5,750,000. The submission does not alter the registered liquidation deadline of March 30, 2028, nor does it report any trust extension or redemption timing adjustments. Why it matters: This filing locks in the post-transaction capital architecture prior to target acquisition. The $230,000,000 trust balance dictates the maximum redemption ceiling for public shareholders, while the $12,650,000 deferred underwriting obligation operates as a merger-related liability that reduces net proceeds available to a future combined entity, as detailed in the balance sheet notes. Regarding sponsor conduct and governance, the document discloses that on March 30, 2026, the company issued 120,000 founder shares to three independent directors at $0.004 per share for $522, with the sponsor subsequently surrendering an equal number of founder shares to the company for no consideration. The unaudited balance sheet shows the registrant carrying a pre-money accumulated deficit of $(9,731,210), which pro forma adjusts to $(11,223,110) following over-allotment settlement, liability fair value changes, and negative additional paid-in capital reclassifications. The filing contains no forward-looking claims regarding customers, projected revenue, addressable market size, business strategy, proprietary technology, partnership agreements, pending litigation, or personnel changes beyond the CFO signature block.

What changed: A Form 8-K current report and accompanying audited financial statements announcing the consummation of KPET Ultra Paceline Corporation’s initial public offering and concurrent private placement on April 1, 2026. According to the registrant's filing, the Company completed its IPO on April 1, 2026, by selling 20,000,000 units at $10.00 per unit to generate $200,000,000 in gross proceeds, and simultaneously sold 235,000 private placement units to KPET Ultra Paceline Unit Holdings, LLC for $2,350,000. The filing states that $200,000,000 of the combined net proceeds, which includes $11,000,000 of deferred underwriting discounts and commissions, was deposited into a trust account with Continental Stock Transfer & Trust Company acting as trustee. Management disclosed that the Company has 24 months from the April 1, 2026 closing to complete an initial business combination, with a one three-month extension available at the Sponsor's option. The document notes the issuance of 5,750,000 founder shares to the Sponsor for $25,000, the March 30, 2026 grant of 120,000 founder shares to three independent directors for an aggregate purchase price of $522, and an administrative support agreement requiring payments of $20,000 per month to a Sponsor affiliate. Underwriters retain a 45-day over-allotment option to purchase up to 3,000,000 additional units, and the Company recorded an over-allotment option liability valued at $158,100. The registrant explicitly stated it had not commenced operations, had not identified a business combination target, and had engaged in no substantive merger discussions. Why it matters: This filing establishes the baseline liquidity, timeline, and contingency rules that will govern future redemption calendar events and extension votes. According to the Notes to Financial Statements, public shareholders may redeem their shares at a per-share price equal to the aggregate amount then on deposit in the Trust Account divided by the number of outstanding public shares, with permitted withdrawals for dissolution expenses limited to up to $100,000 of interest net of taxes payable. The Company outlined that any target business must carry a fair market value equal to at least 80% of the net Trust Account balance at the time a business combination agreement is signed. Regarding sponsor conduct, the filing attributes a letter-agreement indemnification obligation to the Sponsor to cover third-party claims that would reduce Trust assets below the lesser of $10.00 per share or the actual Trust balance, while management cautioned it cannot verify whether the Sponsor possesses sufficient funds to satisfy those liabilities. The document details warrant mechanics, reporting 3,333,333 public warrants and 39,167 private placement warrants outstanding, with public warrants exercisable at $11.50 per share and private warrants expiring five years post-combination. Management confirmed no working capital loans were outstanding as of April 1, 2026, though up to $1,500,000 may be loaned and converted into private placement-equivalent units at $10.00 per unit. These provisions directly dictate capital structure preservation, dilution parameters, and the financial thresholds triggering shareholder action.

What changed: A Schedule 13G beneficial ownership report, classified as a routine SEC compliance exhibit used to declare passive equity positions. Filed on 2026-04-07, the document lists Sculptor Capital LP, Sculptor Capital II LP, Sculptor Capital Holding Corp, Sculptor Capital Holding II LLC, Sculptor Capital Management, Inc., and Sculptor Master Fund, Ltd. as the reporting entities. According to the filing, these parties hold sufficient common stock to trigger mandatory disclosure. The excerpt provides no share counts, percentages, or acquisition purposes. Bearing on SPAC mechanics, the text makes zero references to modifications of the 2028-03-30 redemption deadline, adjustments to the $10.079676130434782 trust per share, or any business combination extensions. Deal progress and sponsor conduct are unaffected by this static ownership snapshot. Why it matters: For investors tracking KPET Ultra Paceline through the searching phase, institutional accumulation often signals which shareholders may align behind a future target or oppose a suboptimal merger. However, because the filing is structured as a passive 13G rather than an activist 13D, the Sculptor entities do not currently claim voting control that would force redemption timeline shifts or dictate trust distribution mechanics. No claims regarding revenue, market size, strategy, technology, partnerships, litigation, or personnel appear in the text. The document serves as a baseline transparency marker; material follow-up requires subsequent amendments detailing actual share volumes, cost basis, or stated intent to influence merger terms.

What changed: A Form 4 – insider ownership report and routine compliance exhibit detailing open-market securities transactions filed with the SEC. The filing reports that on April 1, 2026, Karl Peterson (Director, Chairman, and CEO) and KPThree Capital LLC (identified as a 10% owner) each acquired 235,000 shares via open-market purchases, leaving both with post-transaction holdings of 235,000 shares. The document does not amend the trust/share value of $10.079676130434782, the redemption deadline of March 30, 2028, or the SPAC’s SEARCHING classification. No modifications to extension procedures, trustee duties, or redemption eligibility thresholds are disclosed. Why it matters: Open-market insider accumulation during the search phase typically reflects management conviction regarding target identification timelines, which can indirectly shape shareholder redemption behavior. Because the purchases settled through standard market channels rather than trust accounts, PIPE placements, or underwriter facilities, they exert no immediate pressure on liquidity events or deal financing. The filing attributes all details solely to the reporting persons and their compliance submissions; it contains zero assertions regarding customer concentration, revenue runs, market sizing, technological development, partnership pipelines, operational personnel, or active litigation. Without the issuer’s total outstanding share count, the 235,000-share volume cannot be mathematically converted into a definitive ownership percentage using only the supplied text.

What changed: 8-K filed by SPAC KPET Ultra Paceline Corp reporting its IPO consummation and related agreements. KPET consummated its IPO of 20,000,000 units at $10.00 per unit on April 1, 2026, depositing $200,000,000 (including $11,000,000 deferred underwriting discount) into the trust. Contemporaneously, it sold 235,000 private placement units to Unit Holder Sponsor for $2,350,000. The filing also reports the appointment of three independent directors (Youngblood, Philips, McKee) who each purchased 40,000 Class B shares; the Sponsor concurrently forfeited 120,000 Class B shares. The company's Amended and Restated Memorandum and Articles were adopted. The company has 24 months (27 with sponsor extension) from the IPO closing to complete a business combination. Why it matters: This is the foundational filing for the SPAC. It establishes the trust value per share ($10.079676130434382 based on $200,000,000 / 19,841,880 public shares, though stated as $10.079676130434782), the 24/27-month deadline (April 1, 2028 / April 1, 2029), the redemption mechanics, and the insider lock-ups (Founder Shares: 180 days post-business combination or post-liquidation; Private Units: 30 days post-business combination). The sponsor forfeiture mechanism for the over-allotment is set (up to 750,000 Founder Shares). The independent directors bought in with founder shares, aligning their interests. The filing contains no information on a target, revenue, customers, or market size beyond the SPAC's blank-check nature.

What changed: Investor Prospectus (Filed Pursuant to Rule 424(b)(4)) for an Initial Public Offering. Mechanics & Redemption Calendar: The prospectus establishes a 24-month period from closing to consummate an initial business combination, extendable by one three-month increment at the sponsor’s option, which triggers a simultaneous shareholder redemption opportunity regardless of voting stance. If the extended timeframe lapses without completion, 100% of public shares will be redeemed at a per-share price equal to the aggregate trust account balance divided by outstanding public shares. Why it matters: Strategic Positioning & Pedigree Claims: Management attributes its acquisition framework to over 50 combined years of operational and investment experience, targeting underperforming assets in travel, industrials, technology, telecommunications, media, business services, and consumer products.

What changed: This filing is a Form 3, an SEC insider ownership report submitted by director Kathleen Philips. The filing explicitly states 'No non-derivative transactions or holdings reported,' indicating that the SPAC’s trust/share value of $10.079676130434782 saw no insider transaction activity, the redemption deadline of 2028-03-30 was neither moved nor triggered, the SPAC remains in SEARCHING status, and no new deal advancement or sponsor behavioral shifts are recorded. Why it matters: Because the filing discloses zero changes to equity positions, it provides no data point for tracking internal conviction, redemption window dynamics, extension likelihood, or sponsor conduct. It contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. As a standard regulatory entry with no reported movements, it alters no mechanical parameters for investors monitoring the calendar or trust composition.

What changed: A routine compliance exhibit classified as a Form 3 initial disclosure of beneficial ownership. The submission reports zero non-derivative transactions and no reported share holdings for Director YOUNGBLOOD DR KNEELAND. It introduces no modifications to redemption windows, trust accounting mechanisms, extension provisions, or business combination progression. Sponsor conduct, capital raises, or warrant exercise triggers remain unaddressed. Why it matters: For investors tracking pre-deal SPAC mechanics, the flat-line reporting eliminates insider liquidity events as a near-term catalyst and confirms no directional pressure on the trust balance sheet. The filing contains no substantive operational disclosures: no statements regarding target sector alignment, customer pipelines, projected revenue multiples, technology roadmaps, partnership frameworks, active litigation, or executive appointment changes are attributed to management or the sponsor. Capital preservation and governance stability remain the sole takeaways from this regulatory update.